COL6A3 and undifferentiated pleomorphic sarcoma: Interestingly, increased expression of the cytoskeletal component COL6A3 and biglycan (BGN) was associated with a favorable prognosis in studies of 46 and 38 UPS patients, respectively, despite the potential oncogenic role of the COL6A3-GULP1 fusion [26,51].